The goal of this observational study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main questions it aims to answer are: 1. Does obstruction of the olfactory cleft predict return of the sense of smell? 2. Do electrophysiological signals generated by breathing and sniffing behavior predict return of the sense of smell? Participants starting dupilumab will undergo assessment for their degree of olfactory cleft obstruction, and an electrophysiologic assessment of their olfactory cleft and be followed over 6 months of treatment with dupilumab.
Study Type
OBSERVATIONAL
Enrollment
30
24 weeks of dupilumab 300mg q2 weeks
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
RECRUITINGStatus change of the Brief Smell Identification Test
The brief smell identification test will be administered and patients classified into normal/age-related deficit vs abnormal.
Time frame: 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.